Kline’s Healthcare Industry Manager Laura Mahecha will discuss current trends in the U.S. nonprescription drugs market in a web conference, followed by a live question and answer session. REGISTER Laura will share:
Filed under: Healthcare | Tagged: Nonprescription Drugs Market USA | Leave a Comment »
Over the past few years, Rx-to-OTC switch products have emerged as a major growth driver in the U.S. OTC drug industry. While overall industry growth moderated to just 2.2% in 2008-2009, growth for Rx-to-OTC switches shot up by more than 12%. On the heels of numerous successful switches like Prevacid 24 Hour, Zegerid, Alli, and MiraLax, manufacturers have begun looking ahead at potential switch candidates much earlier in the Rx product life cycle. And with good reason: while the OTC market as a whole is expected to gain with just a CAGR of 2.6% over the next five years, future switches are set to explode by nearly 75%, adding more than $1.5 billion in absolute dollars to the OTC market.
Filed under: Healthcare | Tagged: Alli, MiraLax, Prevacid 24 Hour, Rx-to-OTC switches, Zegerid | Leave a Comment »
Kline is pleased to announce that our research has begun for the OTC Drugs: U.S. Competitor Cost Structures 2010 study. Our lead research analyst, Mr. Prashant Sharma, is currently in touch with suppliers, manufacturers, packaging companies, ad agencies, financial analysts, and OTC marketers to understand how their cost structures have changed recently. We would like your [...]
Filed under: Healthcare | Leave a Comment »
The U.S. OTC market is often a challenging market to make predictions about. There are so many instances where companies, brands, consumers, and even regulators buck trends that there are often reasons to look at things on a case-by case basis. However, when it came to predicting the impact the economic recession of 2008-2009 would [...]
Filed under: Healthcare | Tagged: Nonprescription Drugs Market USA | Leave a Comment »
The years 2008 and 2009 have posed considerable challenges for branded OTC marketers caused by global recession, price-conscious consumers, and strong competition from private labels. However, Rx-to-OTC switch remains a strong prospect for future growth of the industry.
Filed under: Healthcare | Tagged: Rx-to-OTC switch | Leave a Comment »
An FDA advisory committee is weighing in on the safety of OTC acetaminophen, the key active ingredient found in many OTC pain relievers, sleeping aids, and cough and cold medications. The proposed regulations suggest either cutting down dosages of acetaminophen or completely pulling combination drugs that contain acetaminophen off the shelves.
Filed under: Healthcare | Tagged: Acetaminophen regulations | 1 Comment »
Omega-3 represents one of the fastest growing segments in the food ingredients industry, both in the finished food product area and supplement industry. As marketing and promotion drives consumer sales, the ingredient suppliers are also doing there bit to maintain the dynamism of this sector, continuing to shape the finished product industry.
Filed under: Consumer Products, Healthcare | Tagged: food ingredients, Martek, Martek’s life'sDHATM, Omega-3 | Leave a Comment »
The natural personal care market in the U.S. jumped 19% to $2 billion in sales for 2008, Kline’s Natural Personal Care 2008 study revealed earlier this year. Major marketers are in an excellent position to leverage the naturals proposition that began with the smaller niche players. Manufacturing economies of scale, a stronger position for negotiating [...]
Filed under: Consumer Products, Healthcare | Tagged: natural personal care market, natural products, organic beauty products | Leave a Comment »
As we emerge from the global recession of 2008 and 2009, marketers of major OTC brands must be careful to continue to invest in innovations to bring new and improved OTCs to market. Several categories were hard hit by private-label competition as consumers were willing to trade down to less costly store brands during tough economic times. However, market share and sales for branded OTCs can be insulated from private-label competition by offering innovations such as fast-acting, fewer doses, improved drug delivery forms, faster healing times…
Filed under: Healthcare | Tagged: OTC, private label drugs | Leave a Comment »
Private-label OTC medicines were up 8.2% over the same time period, within which antacids and allergy medicines posted the highest growth last year, driven primarily by increases in sales of private-label omeprazole (Procter & Gambles Prilosec OTC) and cetirizine (Johnson & Johnsons Zyrtec). The following two areas distinctively posted very high growth mainly as a [...]
Filed under: Healthcare | Tagged: Healthcare, Posted by Nicole Saullo, Web Designer | Leave a Comment »
Kline Blogs
Geeta Agashe, Vice President - Energy
Carrie Mellage, Director - Consumer Products
Laura Mahecha, Industry Manager - Healthcare
Dennis Fugate, Industry Manager - Specialty Pesticides
Nancy Mills - Industry Manager, Consumer Products
Karen Doskow, Industry Manager, Consumer Products
